AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-16 and is reviewed periodically as new material appears.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The prevailing academic opinion is that the Israelites were a mixture of peoples predominately indigenous to Canaan, with additional input from an Egyptian matrix of peoples, which most likely inspired the Exodus narrative. Israel's demographics were similar to the demographics of Ammon, Edom, Moab and Phoenicia. Israelite cultural identity was defined by a sense of a shared memory of a collective past in the story of Exodus. Cultural boundaries were marked by ritual practices involving body, food, and time, including male circumcision, avoidance of pork consumption and marking time based on the Exodus, the reigns of Israelite kings, and Sabbath observance. The first two practices were observed by neighbouring west Semites besides the Philistines, who were of Mycenaean Greek origin. As a result, intermarriage with other Semites was common. But what distinguished Israelite circumcision from non-Israelite circumcision was its emphasis on 'correct' timing. Israelite circumcision also served as a mnemonic sign for the circumcised, where their 'unnatural' erect circumcised penis would remind them to behave differently in sexual matters. Yom-Tov Lipmann-Muhlhausen suggests that Israelite identity was based on faith and adherence to sex-appropriate commandments. For men, it was circumcision. For women, it was ritual (animal) sacrifice after childbirth (Leviticus 12:6).
== Lactation == No human data is available if the drug is distributed into human milk. Nursing women should either discontinue breast-feeding or Neumega, the decision should take into account the importance of the drug to the mother.
=== Nucleotides === For polynucleic acids (DNA/RNA), the monomers are nucleotides, each of which is made of a pentose sugar, a nitrogenous base and a phosphate group. Nucleotide monomers are found in the cell nucleus. Four types of nucleotide monomers are precursors to DNA and four different nucleotide monomers are precursors to RNA.
Sources: en.wikipedia.org
The matrix (4) is often referred to as the transfer matrix. It is used to evaluate whether an ion will have stable motion. If the absolute value of the trace of this matrix is less than 2 the ion is said to have stable motion. Stable motion simply means that the secular oscillation of the ion has a maximum displacement. When the absolute value of the trace is greater than 2 ion motion is not stable and the displacement of the ion increases with each secular oscillation. Ion trajectories in a linear or 3D DIT as well as in a digital mass filter, may also be calculated using a similar procedure. Unlike stability calculation it is advantageous for the purpose of resolution and accuracy to represent each period of the waveform with an adequate number of constant voltage steps. The trajectory for the constant potential step,
Valve integrated the Havok physics engine, which simulates real-world physics, to reinforce the player's sense of presence and create new gameplay. To experiment, they created a minigame, Zombie Basketball, in which players used a physics-manipulating gun to throw zombies through hoops. In mid-2000, to test the physics and non-player characters, Valve built a battle between rioting citizens and police. In late 2001, Valve began creating a showreel, hoping to demonstrate it at E3 the next year. For several months, Newell let the team work without his input so he could provide unbiased feedback, and focused on developing Steam, Valve's upcoming digital distribution service. The team presented the showreel to Newell, showcasing physics, environments such as the Borealis, and a dialogue-heavy scene with the scientist character Dr. Kleiner. Newell felt the showreel did not adequately show how the physics would affect gameplay and that the Kleiner scene was overlong. Reflecting on the feedback, Laidlaw concluded that the character drama had to support interactivity and gameplay. In September 2002, the team completed a second showreel, featuring a buggy race along the City 17 coast, an encounter with headcrabs on a pier, an alien strider attacking the city, and a greatly shortened Kleiner sequence. In October, Newell told the team they would announce Half-Life 2 at E3 2003 and release it by the end of the year. As with the original Half-Life, the team split into "cabals" working on different levels.
The finding that plants which lack the receptor of karrikin receptor show several developmental phenotypes (enhanced biomass accumulation and increased sensitivity to drought) have led some to speculate on the existence of an as yet unidentified karrikin-like endogenous hormone in plants. The cellular karrikin signalling pathway shares many components with the strigolactone signalling pathway. Triacontanol – a fatty alcohol that acts as a growth stimulant, especially initiating new basal breaks in the rose family. It is found in alfalfa (lucerne), bee's wax, and some waxy leaf cuticles.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.